SCHEMBL347216

SCHEMBL347216

N#C/C=C(/N)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 3/20 0.64
PRSS1 P07477 2/20 0.48
PRSS2 P07478 2/20 0.48
PRSS3 P35030 2/20 0.48
KMT2A Q03164 2/20 0.48
C1S P09871 1/20 0.48
POLB P06746 2/20 0.47
F2 P00734 1/20 0.46
F10 P00742 1/20 0.46
F12 P00748 1/20 0.46
F7 P08709 1/20 0.46
F3 P13726 1/20 0.46
PKM P14618 1/20 0.46
PDE4A P27815 4/20 0.44
PDE4B Q07343 4/20 0.44
PDE4C Q08493 4/20 0.44
PDE4D Q08499 4/20 0.44
BLM P54132 2/20 0.44
TSHR P16473 2/20 0.41
TDP1 Q9NUW8 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10001025 1.00 RECQL (0.64) RECQLPRSS1PRSS2PRSS3KMT2A
SCHEMBL347217 1.00 RECQL (0.64) RECQLPRSS1PRSS2PRSS3KMT2A
SCHEMBL11844408 0.88 RECQL (0.79) RECQLPOLBPDE4APDE4BPDE4C
SCHEMBL28990052 0.88 RECQL (0.79) RECQLPOLBPDE4APDE4BPDE4C
SCHEMBL11844414 0.88 RECQL (0.79) RECQLPOLBPDE4APDE4BPDE4C
SCHEMBL17412169 0.88 RECQL (0.61) RECQLPRSS1PRSS2PRSS3KMT2A
SCHEMBL1163060 0.83 RECQL (0.56) RECQLKMT2AF2F10TSHR
SCHEMBL1163058 0.83 RECQL (0.56) RECQLKMT2AF2F10TSHR
SCHEMBL1163061 0.83 RECQL (0.56) RECQLKMT2AF2F10TSHR
SCHEMBL30267571 0.82 RECQL (0.70) RECQLPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-3970622-A Heat stabilizers for polyvinyl chloride (β-amino-β-arylacrylonitriles) AMERICAN CYANAMID COMPANY (US) 1976-07-20 US claimed
CN-111116416-A Preparation method of β -amino acrylonitrile compound 中国农业大学 2020-05-08 CN disclosed
EP-2782579-B1 PYRAZINE KINASE INHIBITORS PORTOLA PHARM INC (US) 2019-01-02 EP disclosed
WO-2017072796-A1 2-PYRIDONE BASED COMPOUNDS USEFUL AS POTENTIAL PHOSPHODIESTERASE3A (PDE3A)INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-05-04 WO disclosed
EP-2789615-B1 Azaindazoles as Btk kinase modulators and use thereof BRISTOL MYERS SQUIBB CO (US) 2017-05-03 EP disclosed
US-9359308-B2 Pyrazine kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 US disclosed
EP-2072517-B1 Asymmetric phenanthrolins, method for their manufacture and doped organic semiconductor material containing them NOVALED GMBH (DE) 2015-01-21 EP disclosed
US-8877760-B2 Substituted pyrazine-2-carboxamide kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2014-11-04 US disclosed
US-20140309209-A1 Pyrazine Kinase Inhibitors ALEXION PHARMACEUTICALS, INC. 2014-10-16 US disclosed
EP-2789615-A1 Azaindazoles as Btk kinase modulators and use thereof Bristol-Myers Squibb Company (US) 2014-10-15 EP disclosed
US-20070105864-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-05-10 US disclosed
US-20070105864-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-05-10 US disclosed
EP-0799206-B1 ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2002-09-11 EP disclosed
US-6133442-A FOR THE TREATMENT OF DISORDERS WHICH ARE ASSOCIATED WITH ENDOTHELIN ACTIVITIES, ESPECIALLY CIRCULATORY DISORDERS SUCH AS HYPERTENSION, ISCHAEMIA, VASOSPASMS AND ANGINA PECTORIS HOFFMANN-LA ROCHE INC. (US) 2000-10-17 US disclosed
US-5962682-A Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists HOFFMANN-LA ROCHE INC. (US) 1999-10-05 US disclosed
EP-0799206-A1 ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 1997-10-08 EP disclosed
WO-1996019455-A1 ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 1996-06-27 WO disclosed
EP-0129407-A2 Improvements in and relating to (3-aryl-5-isothiazolyl)ureas ELI LILLY AND COMPANY (US) 1984-12-27 EP disclosed
US-3970644-A Heat stabilizers for polyvinyl chloride (β-amino-β-arylacrylamides) AMERICAN CYANAMID COMPANY (US) 1976-07-20 US disclosed
US-3970622-A Heat stabilizers for polyvinyl chloride (β-amino-β-arylacrylonitriles) AMERICAN CYANAMID COMPANY (US) 1976-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309209-A1 Pyrazine Kinase Inhibitors SYK, ZAP70, LCK RECQL 2781/4885PRSS1 876/4885PRSS2 1245/4885
US-20070105864-A1 Methods for inhibiting protein kinases PIM1, PIM2, PIM3 RECQL 1591/4885PRSS1 2447/4885PRSS2 3098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.